Ryan Conor S, Juhn Young J, Kaur Harsheen, Wi Chung-Il, Ryu Euijung, King Katherine S, Lachance Daniel H
Department of Neurology, Mayo Clinic, Rochester, MN.
Department of Pediatrics, Mayo Clinic, Rochester, MN.
Neurooncol Pract. 2020 Jun;7(3):288-298. doi: 10.1093/nop/npz065. Epub 2019 Dec 7.
We assessed glioma incidence and disparities in postglioma survival rate in the Olmsted County, Minnesota, population.
This population-based study assessed the incidence of pathologically confirmed primary gliomas between January 1, 1995, and December 31, 2014. Age- and sex-adjusted incidence rates per 100 000 person-years were calculated and standardized to the US white 2010 population. We compared incidence trends of glioma during our study period with previously published Olmsted County data from 1950 to 1990. We assessed postglioma survival rates among individuals with different socioeconomic status (SES), which was measured by a validated individual HOUsing-based SES index (HOUSES).
We identified 135 incident glioma cases (93% white) with 20 pediatric (50% female) and 115 adult cases (44% female). Overall incidence rate during our study period, 5.51 per 100 000 person-years (95% CI: 4.56-6.46), showed no significant changes and was similar to that seen in 1950 to 1990, 5.5 per 100 000 person-years. The incidence of pediatric (age < 20 years) glioma was 2.49 (95% CI: 1.40-3.58), whereas adult glioma incidence was 6.47 (95% CI: 5.26-7.67). Among those with grade II to IV gliomas, individuals with lower SES (< median HOUSES) had significantly lower 5-year survival rates compared to those with higher SES, adjusted hazard ratio 1.61 (95% CI: 1.01-2.85).
In a well-defined North American population, long-term glioma incidence appears stable since 1950. Significant socioeconomic disparities exist for postglioma survival.
我们评估了明尼苏达州奥姆斯特德县人群中胶质瘤的发病率以及胶质瘤后生存率的差异。
这项基于人群的研究评估了1995年1月1日至2014年12月31日期间经病理确诊的原发性胶质瘤的发病率。计算了每10万人年的年龄和性别调整发病率,并根据2010年美国白人人口进行标准化。我们将研究期间胶质瘤的发病率趋势与之前发表的1950年至1990年奥姆斯特德县的数据进行了比较。我们评估了不同社会经济地位(SES)个体的胶质瘤后生存率,SES通过经过验证的基于个人住房的SES指数(HOUSES)来衡量。
我们确定了135例新发胶质瘤病例(93%为白人),其中20例为儿童病例(50%为女性),115例为成人病例(44%为女性)。我们研究期间的总体发病率为每10万人年5.51例(95%置信区间:4.56 - 6.46),无显著变化,与1950年至1990年每10万人年5.5例的发病率相似。儿童(年龄<20岁)胶质瘤的发病率为2.49(95%置信区间:1.40 - 3.58),而成人胶质瘤的发病率为6.47(95%置信区间:5.26 - 7.67)。在患有II至IV级胶质瘤的患者中,社会经济地位较低(<HOUSES中位数)的个体与社会经济地位较高的个体相比,5年生存率显著较低,调整后的风险比为1.61(95%置信区间:1.01 - 2.85)。
在一个明确界定的北美人群中,自1950年以来胶质瘤的长期发病率似乎稳定。胶质瘤后生存率存在显著的社会经济差异。